Apr 12 |
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
|
Apr 10 |
Ocugen says EU backs a U.S. trial for gene therapy
|
Apr 10 |
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
|
Apr 8 |
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
Apr 8 |
Why Ocugen Shares Are Trading Higher
|
Apr 8 |
Ocugen stock gains after FDA nod to initiate Phase 3 trial of gene therapy candidate
|
Apr 8 |
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
|
Apr 5 |
Why Ocugen Stock Is Climbing Today
|
Apr 5 |
Ocugen advances Phase 1/2 trial for eye disease candidate
|
Apr 5 |
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
|